PRESENT TITLE AND AFFILIATION
Primary Appointment
Associate Professor, Tenure Track, Department of Health Services Research, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
EDUCATION
Degree-Granting Education
Universidad Nacional Autónoma de México, Facultad de Medicina, Mexico City, Mexico, MD, 2003, Medicine
Netherlands Institute of Health and Sciences, Rotterdam, Netherlands, MSc, 2004, Clinical Epidemiology
Postgraduate Training
Clinical Internship, Internal Medicine, Barnes-Jewish Hospital/Washington University School of Medicine, St. Louis, MO, 7/2005-6/2006
Clinical Residency, Internal Medicine, Barnes-Jewish Hospital/Washington University School of Medicine, St. Louis, MO, 7/2006-6/2008
Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2008-6/2011
CREDENTIALS
Board Certification
Internal Medicine, 293632, 2008-2018
Medical Oncology, 293632, 11/2011-2021
Medical Oncology (Mexican Board of Oncology), 5/2016-5/2021
Licensures
Active
Physician Surgeon, Mexico, 3838420, 2/2002
TX, P2211, 2012
Inactive
N/A
EXPERIENCE/SERVICE
Academic Appointments
Assistant Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 8/2011-9/2017
Assistant Professor, Tenure track, Department of Health Services Research, Division of Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2014-9/2017
Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2017-present
Associate Professor, Tenure Track, Department of Health Services Research, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2017-present
Administrative Appointments/Responsibilities
N/A
Other Appointments/Responsibilities
Study Coordinator, Departamento de Oncología, Instituto Nacional de Nutrición Salvador Zubirán, Mexico City, Mexico, 8/2004-5/2005
Medicine Chief Resident, John Cochran VA Medical Center, St. Louis, MO, 6/2007-1/2008
Member, SWOG Breast Committee, Portland, OR, 2011-present
Member, SWOG Breast Committee Working Group, Portland, OR, 2011-present
Member, National Breast Cancer Guideline Committee, Mexico, Mexico, 2012-present
Member, ASCO representative in the Consensus Guideline on margins for invasive breast cancer, SSO/ASTRO, 2013-2014
Member, SWOG Cost-Effectiveness and Outcomes Committee, Portland, OR, 10/2013-present
Member, ASCO Clinical Practice Guideline Committee, Alexandria, VA, 5/2014-6/2017
Liaison Member, ASCO Quality of Care Committee, Alexandria, VA, 7/2014-6/2017
Member, ASCO Guideline Methodology Subcommittee, Alexandria, VA, 7/2014-present
Member, ASCO Representative in the Consensus Guideline on margins for ductal carcinoma in situ cancer, ASCO/SSO/ASTRO, 2015-2016
Member, SWOG CCDR Database Observational Study Working Group, 2015-present
Member, NCCN Foundation Young Investigator Award Review Committee, 2016-present
MD Anderson Physician Network Consultant, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2016-present
Chair Elect, ASCO Clinical Practice Guidelines Committee, Houston, TX, 7/2017-6/2018
Chair, ASCO Clinical Practice Guidelines, Houston, TX, 6/2018-present
Endowed Positions
N/A
Consultantships
N/A
Military or Other Governmental Service
N/A
Institutional Committee Activities
Clinical Research Committee 3, Member, 8/2008-8/2012
MD Anderson Cancer Center at Cooper (MDACCC) Relationship Committee, Member, 2014-present
Mexican American Cohort Internal Advisory Board, Member, 2014-present
Multidisciplinary Breast Cancer Relationship Committee, Member, 2014-present
Charles A. LeMaistre Lecture, Nomination Committee, 8/2015-8/2017
Clinical Effectiveness Subcommittee (CE Subcommittee), Member, 8/2015-present
Department of Health Services Research Faculty Search Committee, Member, 10/2015-7/2017
Health Services Research Monthly Seminar, Program Coordinator, 2016-present
Faculty Senate, Senator, 9/2016-8/2019
Institutional Review Board IV, Member, 9/2016-present
Multidisciplinary Breast Evaluation Group Northwell, Medical Oncology Representative, 2017-present
Israelita Brasileira Hospital Albert Einstein Breast Tumor Board, Medical Oncology Advisor, 2017-present
MD Anderson Cancer Center Patient Advocate Initiative, Medical Oncology Leader Liaison, 2017-present
Symptom Research Chair Search Committee, Member, 2017-present
Chair Symptom Control Search Committee, Member, 2017
HONORS AND AWARDS
Academic Distinction, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, 2001
Achievement Medical Student Award, Universidad Nacional Autónoma de México, 2002
Merit-based Academic CONACYT Scholarship, The National Council for Science and Technology. Mexico, 2003
NIHES Award, Erasmus University Rotterdam, University of Amsterdam, Utrecht University, University of Nijmegen, National Institute of Public Health and Environment, Netherlands Cancer Institute, 2004
Best Poster Award, Mentors in Medicine Research Grant Scientific Symposium. Washington University School of Medicine, 2006
Clinical Scientist Training and Research Program, Barnes Jewish Hospital, Washington University School of Medicine, St. Louis, MO., 2006
Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 2008
Kipnis-Daughaday Teaching Award, Washington University School of Medicine, 2008
AACR Minority Scholar Award, Susan G. Komen for the Cure, 2009
Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 2009
ASCO Cancer Foundation Merit Award, The Breast Cancer Symposium, 2009
Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 2010
ASCO Cancer Foundation Merit Award, The Breast Cancer Symposium, 2010
Selected for participation at the AACR/ASCO Methods in Clinical Cancer Research Workshop, Vail, Colorado, 2010
Achievement in Clinical Research Award, The Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 2011
ASCO Cancer Foundation Merit Award, The Breast Cancer Symposium, 2011
Young Investigator Award, SWOG, 2011
Young Investigator Award, Multinational Association of Supportive Care in Cancer (MASCC), 2015
Top 1% Nationally in CAHPS measures related to patient experience and satisfaction, The University of Texas MD Anderson Cancer Center, 2017
Conquer Cancer Foundation Advanced Clinical Research Award in Breast Cancer, ASCO, 2018
2018 Faculty Scholar Award, The University of Texas MD Anderson Cancer Center, 2018
ASCO Leadership Development Program, ASCO, 2018-present
RESEARCH
Grants and Contracts
Funded
Co-Investigator, 15%, Toxicities of Breast Cancer Treatment, SAC150061, Susan G. Komen Breast Cancer Foundation, PI – Sharon Giordano, 9/1/2015-8/31/2018, $480,000 ($160,000/year)
Co-Investigator, 10%, Comparative Effectiveness Research on Cancer in Texas (CERCIT) 2.0: Project 2, RP160674, Cancer Prevention Research Institute of Texas (CPRIT) Subcontract with UT Medical Branch – Galveston, PI – James Goodwin, 8/31/2016-8/30/2021, $653,150 ($138,310/year)
Principal Investigator, 3%, Association of Body Mass Index (BMI) with emergency room visits and chemotherapy-related hospitalizations among breast cancer patients treated in SWOG clinical trials, NCORP Cancer Care Delivery and The Hope Foundation, 4/1/2018-3/31/2019, $25,000 ($25,000/year)
Principal Investigator, 20%, Understanding barriers and decreasing the time to chemotherapy in a vulnerable population: Pilot study of a targeted intervention, Conquer Cancer Foundation of the American Society of Clinical Oncology, 7/1/2018-6/30/2021 ($137,589/year)
Pending
Co-Investigator, 5%, Targeted Oral Anticancer Agents: Patterns of Indicated and Off-Label Use, the Associated Factors, and Economic Implications, 1 R01 CA225647-01, NIH, PI – Shih, 12/1/2018-11/30/2023, $1,523,103 ($314,369/year)
Other
N/A
Completed
Research Scholar, CERCIT: Comparative Effectiveness Research on Cancer in Texas, RP101207, Cancer Prevention & Research Institute of Texas (CPRIT), PI – James Goodwin, 8/1/2010-7/31/2012, $135,000 ($45,000/year)
Co-Investigator, 2%, CERCIT: Comparative Effectiveness Research on Cancer in Texas (P4: Quality of Supportive Care in Texas), RP140020-P4, Cancer Prevention & Research Institute of Texas (CPRIT), PI – James Goodwin, 3/1/2014-8/29/2016, $489,116 ($244,558/year)
Principal Investigator, 5%, Impact of Oncotype Dx testing on the timing of radiation therapy delivery among breast cancer patients: A population based study, 2015-13015201-Y1, The Center for Radiation Oncology – Health Services Research Seed Grant, 5/1/2015-9/30/2016, $15,000
Principal Investigator, 3%, Racial Disparities among participants in SWOG randomized clinical trials. NCORP Cancer Care Delivery Pilot Award, The Hope Foundation, 1/5/2016-1/5/2017, $25,000 ($25,000/year)
Co-Investigator, 2%, Health Assessment to Advance Cancer Prevention, Screening, and Control in the MD Anderson Cancer Center’s Catchment Area: The State of Texas, 3 P30 CA016672-41S6, NIH/NCI, PI – Ronal DePinho, 9/1/2016-8/31/2017, $125,000 ($125,000/year)
Not Funded
Principal Investigator, PI3K/AKT/mTOR-related protein expression in breast cancer between White, Mexican and Mexican-American women, American Society of Clinical Oncology (ASCO) Young Investigator Award, 2010
Principal Investigator, Adherence, chemotherapy use and cardiac monitoring during adjuvant trastuzumab, National Comprehensive Cancer Network (NCCN) Young Investigator Award, 2011
Principal Investigator, Disparities in the Adherence, monitoring and toxicities of adjuvant trastuzumab, Susan G. Komen for the Cure Catalyst Award on Disparities, 2011
Principal Investigator, Trastuzumab-related cardiotoxicity, American Society of Clinical Oncology (ASCO) Young Investigator Award, 2011
Principal Investigator, Adherence to oral therapy in a phase III randomized placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high risk hormone receptor-positive and Her2-negative breast cancer (S1207), American Society of Clinical Oncology (ASCO) Cancer Foundation Career Development Award, 2013
Principal Investigator, 20%, Adherence to oral therapy in a phase III randomized placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high risk hormone receptor-positive and Her2-negative breast cancer (S1207), American Society of Clinical Oncology (ASCO) Career Investigator Award, 7/1/2014-7/1/2017 ($61,000/year)
Co-Investigator, 8%, Medical and Financial Toxicity among Patients with Breast Cancer: A Comparative Effectiveness Analysis, Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO), PI – Sharon Giordano, 7/1/2015-6/30/2020, $475,000 ($95,000/year)
Co-Investigator, 5%, Finding Optimal Strategies to Manage Cardiotoxicity in Elderly Cancer Patients, NIH, PI – Ya-Chen Tina Shih, 9/1/2015-8/31/2019, $745,073 ($174,565/year)
Principal Investigator, 20%, Clinical trial participation among older breast cancer patients, Susan G. Komen for the Cure. Career Catalyst Award, 7/1/2016-6/30/2019, $358,086 ($119,590/year)
Co-Investigator, 15%, Predictive modeling for the risk of cancer using large scale electronic health records, Cancer Prevention Research Institute of Texas (CPRIT) – Subcontract with UTHSC – Houston, PI – Hua Xu / Sharon Giordano, 12/1/2016-8/31/2019, $284,533 ($94,690/year)
Principal Investigator, 25%, Clinical trial participation among older breast cancer patients, MDACC – Sabin Foundation, 4/1/2017-3/31/2019, $99,954 ($52,850/year)
Principal Investigator, 20%, Clinical trial participation among older breast cancer patients, American Cancer Society (ACS), 7/1/2017-6/30/2021, $665,652 ($164,143/year)
Co-Investigator, 5%, Innovative machine learning methods in medical cost analysis, NIH – Subcontract from Northwestern University, PI – Ya-Chen Tina Shih/, 7/1/2017-6/30/2021, $350,167 ($70,332/year)
Protocols
Funded
Principal Investigator, Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer, SWOGS0307, 2006-present
Collaborator, Quality of Supportive Cancer Care in Texas, DR10-0685, PI – Linda S Elting, 2010-present
Collaborator, Phase Ib Trial Of The Combination Of PI3K Inhibitor BAY 80-6946 And Allosteric-MEK Inhibitor BAY 86-9766 In Subjects With Advanced Cancer, 2011-0327, PI – George R. Blumenschein, Jr., 2011-present
Collaborator, Phase I Open-Label Dose Escalation Study of LJM716 Administered Intravenously in Patients with Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer, 2012-0499, PI – Ana Maria Gonzalez-Angulo, 2012-present
Collaborator, Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-396 in Patients with Advanced Solid Tumors, 2012-0268, PI – George R. Blumenschien, Jr., 2012-present
Collaborator, Phase II, Double-Blind, Placebo-Controlled, Randomized Study of GDC-0941 or GDC-0980 with Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy, 2011-1135, 2012-present
Collaborator, Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination with Trastuzumab in Breast Cancer Patients with Brain Metastases, 2011-0688, PI – Nuhad Ibrahim, 2012-present
Collaborator, A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC 1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2-Advanced or Metastatic Breast Cancer That Has Progressed on Treatment With Everolimus, 2013-0776, PI – Bora Lim, 2013-present, Millennium
Collaborator, Examination of the Concordance between Oncotype DX and Other Molecular Diagnostic Signatures, PA12-1165, PI – Amy Hong Zhang, 2013-present
Collaborator, Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Solid Tumors and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer, 2013-0375, PI – Stacy Moulder, 2013-present
Collaborator, Phase I, First-in-Human, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of X-396 in patients with advanced solid tumors, 2012-0477, PI – George R. Blumenschein, Jr., 2013-present
Collaborator, Phase IA/IB, Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and TOR Kinase Inhibitor, CC-115, Administered Orally to Subjects with Advanced Solid Tumors and He, 2012-0242, PI – George R. Blumenschein, Jr., 2013-present
Principal Investigator, Phase Ib/II Trial of LEE011 in Combination with Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Her2 negative Locally Advanced or Metastatic Breast Cancer, 2013-0468, 2013-present, Novartis
Collaborator, Phase II Study of Denosumab to Define the Role of Bone Related Biomarkers in Breast Cancer Bone Metastasis, 2013-0007, PI – Naoto Ueno, 2013-present
Principal Investigator, Phase III Randomized, Placebo-Control Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer, SWOG 1207, 2013-present, PI Funded by the NCI (NCT01674140)
Collaborator, Randomized Pre-Surgical Pharmacodynamics Study to Assess the Biological Activity of LEE011 Plus Letrozole Versus Single Agent Letrozole on Primary Breast Cancer, 2013-0534, PI – Funda Meric-Bernstam, 2013-present, ALLIANCE – A011202
Collaborator, Randomized, Multicenter, Double-Blind Phase III Study of Pd-0332991 (Oral Cdk 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole for the Treatment of Postmenopausal Women with Er (+), Her2 (-) Breast Cancer who have not Received any Prior Systemic Therapy, 2013-0258, PI – Stacy Moulder, 2013-present
Collaborator, A Phase II Trial of HKI-272 (Neratinib) and Capecitabine for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases, 2013-1007, PI – Nuhad K Ibrahim, 2014-present, Breast Cancer Research Foundation, Dana Farber, Translational Breast Cancer Research Consortium, Puma Biotechnology, Inc.
Co-Principal Investigator, A Randomized Double-Blind, Placebo-Controlled Study of LEE011 in Combination with Letrozole for the Treatment of Postmenopausal Women with Hormone Receptor Positive, HER2-Negative, Advanced Breast Cancer who Received No Prior Therapy for Advanced Disease, 2013-0846, PI – Gabriel N Hortobagyi, 2014-present, Novartis
Collaborator, Assessment of the Tumor Response to Neoadjuvant Chemotherapy in Women with Invasive Breast Cancer using Tc99m sestamibi Molecular Breast Imaging: A Prospective Study., 2014-0812, PI – Gaiane Margishvili Rauch, 2014-present, Diagnostic Imaging Clinical Research Committee Grant
Collaborator, Comparing the Performance of Full-Field Digital Mammography (FFDM), Digital Breast Tomosynthesis (DBT) and Breast MRI in the Preoperative Imaging Evaluation Breast Cancer: A Prospective Study, 2014-0166, PI – Rosalind Pitpitan Candelaria, 2014-present, Diagnostic Imaging Clinical Research Committee Grant
Collaborator, Impact of the Oncotype DX? DCIS Score on Treatment Decision Making in Patients with Ductal Carcinoma in Situ, 2013-0849, PI – Henry Kuerer, 2014-present, Genomic Health, Inc.
Collaborator, Incremental cancer detection utilizing Breast Ultrasound versus Breast MRI in the evaluation of ACR Category 6 breast cancer patients., PA14-0801, PI – Wei Tse Yang, 2014-present
Collaborator, Measurements of Breast Tissue Optical Properties with Diffuse Optical Spectroscopic Imaging (DOSI), 2014-0238, PI – Wei Tse Yang, 2014-present, UCI – Beckman Laser Institute
Collaborator, Ultrasound (US) Imaging Lexicon of Axillary lymph nodes in Patients with Breast Cancer, PA14-0227, PI – Wei Tse Yang, 2014-present
Collaborator, A Companion Sample Collection Protocol to Support the Discovery of the Mechanisms of Resistance to Targeted Cancer Therapies, PA14-1013, PI – Funda Meric-Bernstam, 2015-present, Novartis
Unfunded
Principal Investigator, Long-term outcomes in patients with node-negative invasive breast cancer 1cm or less in greatest diameter (T1a,bN0M0), RCR04-0880, 2005-present
Principal Investigator, Prognostic factors for long-term outcomes in patients with node-negative invasive breast cancer 1cm or less in greater diameter (T1a,bN0M0), LAB05-0457, 2006-present
Principal Investigator, Response to Primary Systemic Chemotherapy: Its effect on long term outcome, RCR07-0159, 2007-present
Co-Principal Investigator, Breast Cancer Evaluation and Targeted Investigational Therapy, LAB11-0337, PI – Ricardo Alvarez, 2011-present
Collaborator, Patterns of care for breast cancer treatment, DR11-0100, PI – Sharon Hermes Giordano, 2011-present
Principal Investigator, Adherence and Treatment-Related Complications in Breast Cancer Patients, PA11-1155, 2012-present
Collaborator, Clinical relevance of additional MDACC Mammography and Ultrasound work up for ACR Category 6 breast cancer patients, PA13-0675, PI – Rosalind Pitpitan Candelaria, 2013-present
Collaborator, Correlating Fine Needle Aspiration to Surgical Excision to Assess for Eradication of Nodal Metastases after Chemotherapy in Breast Cancer, 2013-0877, PI – Abigail Suzanne Caudle, 2013-present
Co-Principal Investigator, Benefits and Risks of Participating in Clinical Trials for Older Cancer Patients, PA14-0028, PI – Sharon Hermes Giordano, 2014-present
Collaborator, Evaluation of biologic markers in determining prognosis in breast cancer patients, PA14-0710, PI – Elizabeth Mittendorf, 2014-present
Collaborator, Patterns, Costs, and Outcomes of Cancer Care, PA14-0949, PI – Sharon Hermes Giordano, 2014-present
Principal Investigator, Time to adjuvant chemotherapy among breast cancer patients in the California Cancer Registry, PA14-0458, 2014-present
